SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec spurts on inking pact to divest 100% stake in NewRise Healthcare

21 Apr 2017 Evaluate

Panacea Biotec is currently trading at Rs. 165.10, up by 6.00 points or 3.77% from its previous closing of Rs. 159.10 on the BSE.

The scrip opened at Rs. 160.90 and has touched a high and low of Rs. 174.40 and Rs. 156.20 respectively. So far 117482 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 178.30 on 27-Jan-2017 and a 52 week low of Rs. 85.50 on 26-May-2016.

Last one week high and low of the scrip stood at Rs. 174.40 and Rs. 152.45 respectively. The current market cap of the company is Rs. 1009.41 crore.

The promoters holding in the company stood at 74.60%, while Institutions and Non-Institutions held 0.06% and 25.34% respectively.

Panacea Biotec has entered into a definitive agreement to divest its 100% stake held in NewRise Healthcare (NHPL) which has set up a multi-speciality hospital at Gurugram which is near completion, to Narayana Hrudayalaya (NH).

Under the definitive agreement, the company has agreed to sell its 100% equity shares in NHPL to NH and the company's associate company PanEra Biotec has agreed to sell 100% preference shares in NHPL to NH.  

Panacea Biotec is one of India’s leading research based Biopharmaceutical Company with established research, manufacturing and marketing capabilities. The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.


Panacea Biotec Share Price

388.15 -16.85 (-4.16%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×